Bridgeway Capital Management
LYEL icon

Bridgeway Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Bridgeway Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Hold
18,000
– – ﹤0.01% 1012
2026
Q1 		$361K Hold
18,000
– – 0.01% 890
2025
Q4 		$554K Hold
18,000
– – 0.01% 801
2025
Q3 		$292K Hold
18,000
– – 0.01% 933
2025
Q2 		$159K Buy
+18,000
New +$164K ﹤0.01% 1006

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Bridgeway Capital Management's LYEL Position: Q2 2026 in Review

Bridgeway Capital Management held its Lyell Immunopharma (LYEL) position steady in Q2 2026 at 18,000 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #1012.

Bridgeway Capital Management first reported a position in LYEL in Q2 2025 and has held it in 5 quarters since. The position peaked at $554K in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Bridgeway Capital Management held 18,000 shares of Lyell Immunopharma worth $253K as of Q2 2026.
  • Bridgeway Capital Management left its Lyell Immunopharma share count unchanged in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1012 holding.
  • Bridgeway Capital Management first reported a position in Lyell Immunopharma in Q2 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Lyell Immunopharma position peaked at $554K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.